As you might know, MedPlus Health Services Limited (NSE:MEDPLUS) recently reported its first-quarter numbers. Results were roughly in line with estimates, with revenues of ₹19b and statutory earnings per share of ₹18.29. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the most recent consensus for MedPlus Health Services from six analysts is for revenues of ₹81.3b in 2027. If met, it would imply a modest 7.1% increase on its revenue over the past 12 months. Statutory earnings per share are forecast to reduce 3.1% to ₹17.03 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹80.8b and earnings per share (EPS) of ₹17.10 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
View our latest analysis for MedPlus Health Services
It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹952. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on MedPlus Health Services, with the most bullish analyst valuing it at ₹1,190 and the most bearish at ₹760 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await MedPlus Health Services shareholders.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the MedPlus Health Services' past performance and to peers in the same industry. It's pretty clear that there is an expectation that MedPlus Health Services' revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 9.6% growth on an annualised basis. This is compared to a historical growth rate of 15% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 7.4% per year. So it's pretty clear that, while MedPlus Health Services' revenue growth is expected to slow, it's still expected to grow faster than the industry itself.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ₹952, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for MedPlus Health Services going out to 2029, and you can see them free on our platform here.
Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.